Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. Presenting below are its Q1 FY26 earnings.
Q1 FY26 Earnings Summary
-
Consolidated Revenue from Operations: ₹6,268 crore, up 11.9% year-over-year (YoY) from ₹5,514.3 crore in Q1 FY25.
-
EBITDA: ₹1,806.3 crore, up 38% YoY; EBITDA margin expanded sharply to 29.3% from 23.7% YoY.
-
Profit Before Tax (PBT): ₹1,415.5 crore, up 42.6% YoY.
-
Net Profit (PAT): ₹1,221 crore, up 51.4% YoY from ₹805.5 crore.
-
Gross Profit: ₹4,391.9 crore; margin at 71.3%.
-
EPS: ₹26.69, up ₹51.8% on the YOY basis.
-
Region Performance:
-
U.S. Revenue: ₹2,404 crore (+24.3% YoY), 39% of global sales.
-
India Revenue: ₹2,089 crore (+7.8% YoY), 34% of global sales.
-
Other Developed Markets: ₹775 crore (+17.4% YoY).
-
Emerging Markets: ₹652 crore (+5.2% YoY).
-
API Segment: ₹243 crore, down 33% YoY.
-
-
Expenses:
-
Personnel Costs: ₹1,083 crore, 17.6% of sales.
-
Manufacturing & Other Expenses: ₹1,772 crore, 28.7% of sales.
-
R&D Investment: ₹484 crore, 7.9% of sales.
-
-
Operational Highlights: Robust US generics and India formulations growth; highest-ever Q1 US sales; focus on cost optimization and product mix improvement.
-
Balance Sheet: Net debt position improved to a net cash balance (-₹1,238.6 crore).
Key Management Commentary & Strategic Highlights
-
Managing Director Nilesh Gupta: “We continue to build strong business momentum, anchored by a robust product portfolio, improved efficiencies, and effective use of assets and investments. Our sharpened focus on compliance, innovation, and technology positions us to further unlock sustainable growth.”
-
Growth Drivers: US business momentum (new launches, strong generics pipeline, leading share in key molecules); steady Indian branded business; cost management; margin expansion from operational efficiencies.
-
Strategic Focus: Increasing investment in R&D for specialty and complex generics, further strengthening of quality/compliance, and digitalization of operations. Management strikes an optimistic outlook on sustaining double-digit growth and margin improvement in coming quarters.
Q4 FY25 Earnings Summary
-
Revenue from Operations: ₹5,667 crore, up 14.2% YoY.
-
Net Profit (PAT): ₹782 crore, up 112% YoY from ₹368 crore.
-
EBITDA: ₹1,378 crore, margin at 24.8% (up from 21% YoY).
-
Region Highlights: North America revenue up 19% YoY (₹2,261 crore), India up 6.9% YoY (₹1,711 crore).
-
Full Year FY25: Sales ₹22,192 crore (+12.9% YoY); PAT ₹3,306 crore (+70.8% YoY); EBITDA ₹5,479 crore (+39.4% YoY); margin up 469 basis points to 24.7%.
-
Management Commentary: Q4 and FY25 marked by strong growth in both topline and profitability due to new products and improved margins through operational excellence.
To view the previous earnings of the company, click here